Skip to content
StackItSmart
CCase reports / series

DSIP

Delta Sleep-Inducing Peptide

DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid endogenous neuropeptide first isolated from rabbit brain in the 1970s and later shown to occur naturally in human tissues, plasma and breast milk. It has been studied in small human trials for insomnia, drug/alcohol withdrawal and chronic pain, but the evidence is weak: the best-controlled sleep studies found effects too small to be clinically meaningful, and the withdrawal and pain data come only from uncontrolled open-label series. The main dangers are that there is essentially no modern safety data, no long-term human data, and no pharmaceutical-grade product — DSIP sold to consumers is an unregulated research chemical of unknown purity, sterility and content, injected without medical supervision. All historical human dosing was intravenous under clinical monitoring, not self-administered. Because it crosses the blood-brain barrier and modulates neuroendocrine and autonomic systems, unmonitored use carries unquantified neuropsychiatric, cardiovascular and endocrine risk. Anyone considering it should treat efficacy as unproven and safety as unknown, and involve a physician.

Clinical readoutPeptide · neuropeptide
Hepatic strainNone
CardiovascularModerate
HPTA suppressionNone
Half-life
4 min
Route
All human studies used…
Evidence
C
Active
Discrepant with the ver…
4 min8 min12 min16 min20 min
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ No validated human pharmacokinetic data. In animals DSIP is cleared from plasma extremely rapidly — mean half-life ~4.0 min in dogs, ~2.9 min in a monkey and ~2.0 min in rats (Kato 1984). Human elimination is presumed similarly rapid.
Pharmacology

Mechanism of action

DSIP is the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, an endogenous neuromodulator rather than a classical receptor agonist. Its precise mechanism is not established. Proposed actions include modulation of central slow-wave sleep-generating circuits, interaction with endogenous opioid/opiatergic systems (an early hypothesis that its withdrawal-suppressing effect is naloxone-reversible and thus opioid-receptor mediated), modulation of neurotransmitter and neuroendocrine release (corticotropin, somatotropin, LH, MAO-A activity) and influence on circadian rhythmicity and stress/autonomic regulation. No specific high-affinity DSIP receptor has been definitively characterized, and much mechanistic work is preclinical.
Kinetics

Pharmacokinetics

Half-life

No validated human pharmacokinetic data. In animals DSIP is cleared from plasma extremely rapidly — mean half-life ~4.0 min in dogs, ~2.9 min in a monkey and ~2.0 min in rats (Kato 1984). Human elimination is presumed similarly rapid.

Active duration

Discrepant with the very short plasma half-life: acute subjective/EEG effects on human sleep were reported within a ~130-min window after IV dosing, and 'delayed' effects on the following night's sleep were described — implying central effects outlast plasma presence. Duration is poorly defined and not reliably established.

Route

All human studies used intravenous administration (typically 25 nmol/kg). No controlled human data exist for subcutaneous, intranasal or oral routes commonly used by consumers; oral bioavailability of a peptide is expected to be negligible due to gastrointestinal proteolysis.

Metabolism & clearance

Rapid enzymatic degradation by plasma and tissue peptidases/aminopeptidases; measured metabolic clearance rate ~30.7 ml/kg/min in dogs (Kato 1984). Lipophilicity and plasma half-life govern CNS penetration across the blood-CSF barrier (Banks 1986). This information is for understanding washout/monitoring, not for evading detection.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Reported acute increase in total sleep time and sleep efficiency and shorter sleep latency after IV dosing in small studies, without classic pharmacologic sedation
  • In small controlled insomnia trials, objective sleep changes were statistically weak and judged to be of little clinical significance
  • Open-label reports of rapid suppression of somatic alcohol- and opiate-withdrawal signs, with anxiety resolving more slowly
  • Open-label pilot report of reduced pain levels and concomitant reduction in depressive symptoms in patients with chronic pain (migraine, vasomotor headache, tinnitus, psychogenic pain)
  • Endogenously present in humans (detected in plasma, placenta and breast milk), consistent with a physiological neuromodulatory role
Safety

Adverse effects by system

Cardiovascular

No adequate human safety data. Animal work suggests DSIP can modulate autonomic/cardiac regulation (vagal enhancement, antiarrhythmic effects under stress), but cardiovascular safety in humans is unstudied and unknown.

Hepatic

No human data. Hepatotoxicity has not been studied or reported; as a small peptide not known to undergo hepatic first-pass toxic metabolism, liver injury is not an established risk but cannot be excluded given absent data.

Endocrine / HPTA

No evidence of gonadal-axis (HPTA) suppression. Preclinical data indicate DSIP can modulate hypothalamic-pituitary secretion (corticotropin, somatotropin, LH, cortisol rhythms), but human endocrine effects of exogenous DSIP are not established.

Reproductive

No human data on fertility or pregnancy outcomes. DSIP-like material occurs endogenously in placenta and breast milk, but exogenous administration has not been studied for reproductive safety; use in pregnancy/lactation is unstudied and should be avoided.

Neuropsychiatric

Limited human data. Small studies reported improved mood/reduced depressive symptoms and no psychological side effects, but neuropsychiatric safety of unsupervised use is unstudied; a centrally active neuropeptide could plausibly affect mood, arousal or sleep architecture unpredictably.

Renal

No human data. Renal effects have not been characterized; no reported nephrotoxicity, but safety is unknown.

Hematologic

No human data. Hematologic effects have not been reported or studied.

Dermatologic

No systematic human data. As an injected peptide, local injection-site reactions and, with non-sterile unregulated product, infection/abscess are plausible risks not captured in the clinical literature.

Recovery

HPTA suppression & recovery

Suppression: No evidence of hypothalamic-pituitary-gonadal (HPTA) suppression

DSIP is a neuropeptide, not an androgen or anabolic agent, and there is no evidence it suppresses the gonadal axis, so SERM-based recovery is not applicable and no SERM is indicated for DSIP use. Preclinical data show DSIP can modulate hypothalamic-pituitary secretion generally, so any perceived hormonal changes or symptoms should be evaluated with bloodwork and managed by an endocrinologist rather than self-treated. If a SERM is ever being considered for an unrelated hormonal issue, that decision belongs to an endocrinologist and would be single-agent only.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and periodic complete blood countComprehensive metabolic panel including liver enzymes (ALT/AST, bilirubin) and renal function (creatinine, eGFR)If any hormonal symptoms, an endocrine panel (e.g., cortisol, LH/FSH, testosterone) interpreted by an endocrinologistThere is no validated therapeutic drug level or monitoring assay for DSIP in routine clinical use

Cadence: No evidence-based cadence exists. Given the absence of safety data, obtain baseline bloodwork before any use, involve a clinician, and re-check if symptoms arise; do not rely on labs to make an unproven therapy safe.

Warning signs — seek care
  • Chest pain, palpitations, irregular heartbeat, fainting
  • Signs of allergic/anaphylactic reaction (rash, swelling, difficulty breathing)
  • Injection-site redness, pain, swelling, pus or fever (infection)
  • New or worsening mood changes, confusion, excessive sedation or disturbed sleep
  • Any unexpected or severe symptom — stop and seek medical care
Do not use if

Contraindications

  • Pregnancy and breastfeeding (no reproductive safety data)
  • Use of unregulated, non-pharmaceutical-grade product of unknown purity/sterility (a practical contraindication to self-administration)
  • Known hypersensitivity to the peptide or excipients
  • Any use without physician oversight in people with cardiac, psychiatric, endocrine or substance-use conditions, given unquantified interactions and modulation of opioid/neuroendocrine and autonomic systems
  • Concurrent CNS depressants, opioids or sleep agents (unstudied additive/interactive effects on sedation, respiration and withdrawal physiology)
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Efficacy is unproven and safety is essentially unknown — treat DSIP as experimental, not therapeutic; the best-controlled human sleep trials found effects too small to matter.
  • There is no pharmaceutical-grade DSIP; consumer product is an unregulated research chemical of unverified identity, purity and sterility. This is a core reason not to inject it outside a study.
  • All historical human use was intravenous under clinical monitoring; self-injection by other routes has no safety or efficacy data.
  • Do not combine with opioids, alcohol, benzodiazepines or other sedatives — interactions with sleep, respiration and withdrawal physiology are unstudied.
  • Get baseline bloodwork (CBC, liver and kidney panels) and involve a clinician before any use; DSIP is not a substitute for evidence-based treatment of insomnia, pain or substance withdrawal — supervised medical detox is the standard of care for withdrawal.
  • Stop immediately and seek care for chest pain, palpitations, fainting, allergic reactions, injection-site infection, fever, or significant mood/cognitive changes.
  • Avoid entirely in pregnancy and breastfeeding, and if you have cardiac, psychiatric, endocrine or substance-use conditions manage those with a physician.
  • For any hormonal symptoms, see an endocrinologist rather than self-treating; SERMs are not indicated for DSIP.
Evidence

Citations (14)

Every clinical claim above is tied to a primary source. Overall evidence grade C — graded to the best available evidence for its core claims.

  1. 01

    DSIP is a nine-amino-acid neuropeptide studied for sleep and reviewed in an anaesthesia context

    ReviewDelta sleep-inducing peptide.PMID 11437870 ↗

  2. 02

    In a double-blind RCT, synthetic DSIP improved sleep in insomniacs after IV administration

    RCTSynthetic delta-sleep-inducing peptide improves sleep in insomniacs.DOI 10.1016/s0140-6736(81)92417-x ↗

  3. 03

    In 6 normal volunteers, IV DSIP (25 nmol/kg) acutely increased sleep by ~59% within ~130 min and had delayed positive effects on subsequent night sleep, without classic sedation, and was well tolerated with no observed side effects

    RCTAcute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.PMID 6895513 ↗

  4. 04

    In a double-blind crossover study of chronic insomniacs, DSIP increased total/NREM sleep but changes were not significant versus baseline/placebo and sleep improvement was of little clinical significance

    RCTStudy of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.PMID 3583493 ↗

  5. 05

    In a double-blind RCT in 16 chronic insomniacs, DSIP produced only weak effects and was concluded not likely to be of major therapeutic benefit

    RCTEffects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.DOI 10.1159/000118919 ↗

  6. 06

    Review summarizing DSIP injection studies in insomnia including single-dose improvement and normalization after repeated dosing

    ReviewDSIP in insomnia.DOI 10.1159/000115714 ↗

  7. 07

    Open study of 10-injection DSIP series in 7 severe insomniacs reported normalized sleep and improved daytime mood/performance

    Case seriesA clinical trial with DSIP.DOI 10.1159/000115717 ↗

  8. 08

    In 67 patients with alcohol or opiate withdrawal, single IV DSIP (25 nmol/kg) as sole treatment produced rapid, lasting suppression of somatic withdrawal signs with slower anxiety resolution and no major side effects (open-label)

    Case seriesSuccessful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.DOI 10.1159/000118012 ↗

  9. 09

    In 107 inpatients with alcohol/opiate withdrawal, IV DSIP improved clinical withdrawal signs; tolerance was good aside from headaches reported by a few patients (open-label)

    Case seriesDSIP in the treatment of withdrawal syndromes from alcohol and opiates.DOI 10.1159/000115715 ↗

  10. 10

    Open-label pilot in 7 chronic-pain patients: IV DSIP significantly lowered pain in 6/7 and reduced concomitant depressive states

    Case seriesTherapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.DOI 10.1159/000115716 ↗

  11. 11

    DSIP-like material is present endogenously in humans (detected in breast milk, colostrum, plasma and placenta)

    PreclinicalPresence of delta-sleep-inducing peptide-like material in human milk.DOI 10.1210/jcem-59-1-127 ↗

  12. 12

    DSIP is cleared from plasma very rapidly, with mean half-life ~4.0 min (dog), ~2.9 min (monkey), ~2.0 min (rat) and MCR ~30.7 ml/kg/min in dogs

    PreclinicalDevelopment of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs.DOI 10.1159/000123952 ↗

  13. 13

    DSIP penetrates the blood-CSF barrier in a manner dependent on plasma level, plasma half-life and lipophilicity

    PreclinicalEntry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters.DOI 10.1016/0361-9230(86)90111-5 ↗

  14. 14

    Preclinical data suggest DSIP modulates cardiac/autonomic function with vagal-enhancing and antiarrhythmic effects under stress

    Preclinical[Delta-sleep peptide as a modulator of cardiac activity: theoretical recommendations for practice].PMID 2197498 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice